189 related articles for article (PubMed ID: 11876695)
1. Acid suppression in healthy subjects following lansoprazole or pantoprazole.
Huang JQ; Goldwater DR; Thomson AB; Appelman SA; Sridhar S; James CF; Chiu YL; Pilmer BL; Keith RG; Hunt RH
Aliment Pharmacol Ther; 2002 Mar; 16(3):425-33. PubMed ID: 11876695
[TBL] [Abstract][Full Text] [Related]
2. Effects on 24-hour intragastric pH: a comparison of lansoprazole administered nasogastrically in apple juice and pantoprazole administered intravenously.
Freston J; Chiu YL; Pan WJ; Lukasik N; Täubel J
Am J Gastroenterol; 2001 Jul; 96(7):2058-65. PubMed ID: 11467632
[TBL] [Abstract][Full Text] [Related]
3. Twenty-four-hour monitoring of intragastric acidity: comparison between lansoprazole 30mg and pantoprazole 40mg.
Florent C; Forestier S
Eur J Gastroenterol Hepatol; 1997 Feb; 9(2):195-200. PubMed ID: 9058634
[TBL] [Abstract][Full Text] [Related]
4. A comparison of simplified lansoprazole suspension administered nasogastrically and pantoprazole administered intravenously: effects on 24-h intragastric pH.
Täubel JJ; Sharma VK; Chiu YL; Lukasik NL; Pilmer BL; Pan WJ
Aliment Pharmacol Ther; 2001 Nov; 15(11):1807-17. PubMed ID: 11683695
[TBL] [Abstract][Full Text] [Related]
5. Lansoprazole regimens that sustain intragastric pH > 6.0: an evaluation of intermittent oral and continuous intravenous infusion dosages.
Metz DC; Amer F; Hunt B; Vakily M; Kukulka MJ; Samra N
Aliment Pharmacol Ther; 2006 Apr; 23(7):985-95. PubMed ID: 16573801
[TBL] [Abstract][Full Text] [Related]
6. Twenty-four-hour intragastric pH profiles and pharmacokinetics following single and repeated oral administration of the proton pump inhibitor pantoprazole in comparison to omeprazole.
Hartmann M; Theiss U; Huber R; Lühmann R; Bliesath H; Wurst W; Lücker PW
Aliment Pharmacol Ther; 1996 Jun; 10(3):359-66. PubMed ID: 8791964
[TBL] [Abstract][Full Text] [Related]
7. Intragastric acid control in non-steroidal anti-inflammatory drug users: comparison of esomeprazole, lansoprazole and pantoprazole.
Goldstein JL; Miner PB; Schlesinger PK; Liu S; Silberg DG
Aliment Pharmacol Ther; 2006 Apr; 23(8):1189-96. PubMed ID: 16611280
[TBL] [Abstract][Full Text] [Related]
8. Dose-dependent control of intragastric pH by pantoprazole, 10, 20 or 40 mg, in healthy volunteers.
Tutuian R; Katz PO; Bochenek W; Castell DO
Aliment Pharmacol Ther; 2002 Apr; 16(4):829-36. PubMed ID: 11929403
[TBL] [Abstract][Full Text] [Related]
9. Esomeprazole 40 mg provides more effective intragastric acid control than lansoprazole 30 mg, omeprazole 20 mg, pantoprazole 40 mg and rabeprazole 20 mg in patients with gastro-oesophageal reflux symptoms.
Röhss K; Lind T; Wilder-Smith C
Eur J Clin Pharmacol; 2004 Oct; 60(8):531-9. PubMed ID: 15349707
[TBL] [Abstract][Full Text] [Related]
10. Gastric acid control with esomeprazole, lansoprazole, omeprazole, pantoprazole, and rabeprazole: a five-way crossover study.
Miner P; Katz PO; Chen Y; Sostek M
Am J Gastroenterol; 2003 Dec; 98(12):2616-20. PubMed ID: 14687806
[TBL] [Abstract][Full Text] [Related]
11. The comparative effects of lansoprazole, omeprazole, and ranitidine in suppressing gastric acid secretion.
Blum RA; Shi H; Karol MD; Greski-Rose PA; Hunt RH
Clin Ther; 1997; 19(5):1013-23. PubMed ID: 9385488
[TBL] [Abstract][Full Text] [Related]
12. The acidity index: a simple approach to the measurement of gastric acidity.
Tutuian R; Castell DO; Xue S; Katz PO
Aliment Pharmacol Ther; 2004 Feb; 19(4):443-8. PubMed ID: 14871284
[TBL] [Abstract][Full Text] [Related]
13. Effects of rabeprazole, lansoprazole and omeprazole on intragastric pH in CYP2C19 extensive metabolizers.
Saitoh T; Fukushima Y; Otsuka H; Hirakawa J; Mori H; Asano T; Ishikawa T; Katsube T; Ogawa K; Ohkawa S
Aliment Pharmacol Ther; 2002 Oct; 16(10):1811-7. PubMed ID: 12269976
[TBL] [Abstract][Full Text] [Related]
14. Equipotent inhibition of gastric acid secretion by equal doses of oral or intravenous pantoprazole.
Hartmann M; Ehrlich A; Fuder H; Lühmann R; Emeklibas S; Timmer W; Wurst W; Lücker PW
Aliment Pharmacol Ther; 1998 Oct; 12(10):1027-32. PubMed ID: 9798809
[TBL] [Abstract][Full Text] [Related]
15. Dose-response relationship of lansoprazole to gastric acid antisecretory effects.
Blum RA; Hunt RH; Kidd SL; Shi H; Jennings DE; Greski-Rose PA
Aliment Pharmacol Ther; 1998 Apr; 12(4):321-7. PubMed ID: 9690720
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics and effect on caffeine metabolism of the proton pump inhibitors, omeprazole, lansoprazole, and pantoprazole.
Andersson T; Holmberg J; Röhss K; Walan A
Br J Clin Pharmacol; 1998 Apr; 45(4):369-75. PubMed ID: 9578184
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics, metabolism and interactions of acid pump inhibitors. Focus on omeprazole, lansoprazole and pantoprazole.
Andersson T
Clin Pharmacokinet; 1996 Jul; 31(1):9-28. PubMed ID: 8827397
[TBL] [Abstract][Full Text] [Related]
18. Acid inhibition on the first day of dosing: comparison of four proton pump inhibitors.
Pantoflickova D; Dorta G; Ravic M; Jornod P; Blum AL
Aliment Pharmacol Ther; 2003 Jun; 17(12):1507-14. PubMed ID: 12823153
[TBL] [Abstract][Full Text] [Related]
19. Inhibitory effects of intravenous lansoprazole 30 mg and pantoprazole 40 mg twice daily on intragastric acidity in healthy Chinese volunteers: a randomized, open-labeled, two-way crossover study.
Zhan XB; Guo XR; Li ZS; Gong YF; Gao J; Liao Z; Li Z; Gao S; Liu P
Med Sci Monit; 2012 Feb; 18(2):CR125-130. PubMed ID: 22293876
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of pentagastrin-stimulated gastric acid secretion by pantoprazole and omeprazole in healthy adults.
Pratha VS; Hogan DL; Lane JR; Williams PJ; Burton MS; Lynn RB; Karlstadt RG
Dig Dis Sci; 2006 Jan; 51(1):123-31. PubMed ID: 16416224
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]